Wegovy or Mounjaro Denied by Insurance? Your Appeal Guide

Wegovy (semaglutide 2.4 mg) and Mounjaro/Zepbound (tirzepatide) are the most-denied medications in the United States by volume. Both have extraordinary clinical evidence — the SELECT trial showed semaglutide reduced major adverse cardiovascular events by 20 percent in patients with obesity and cardiovascular disease, while the SURMOUNT-1 trial showed tirzepatide produced 22.5 percent average body weight reduction at 72 weeks. Despite this, most commercial plans and employer-sponsored ERISA plans exclude or restrict these medications, and Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization Denial Rates by Insurer (2026)" class="auto-link">denial rates are among the highest of any drug class. This guide explains the most effective appeal strategies for both drugs.

Why Insurers Deny Wegovy and Mounjaro Claims

Anti-obesity medication formulary exclusion. The most prevalent denial. Many employer-sponsored ERISA plans and commercial plans categorically exclude weight-loss medications. Self-funded ERISA plans are not subject to state insurance mandates, making the exclusion difficult but not impossible to challenge.

BMI or comorbidity criteria not met. Wegovy's FDA indication requires BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Mounjaro's FDA approval is for type 2 diabetes; Zepbound (tirzepatide's obesity formulation) has a separate approval. Insurers may apply more restrictive thresholds than the FDA indication.

Step therapy not completed. Insurers require documented failure of supervised diet programs, behavioral interventions, or older anti-obesity medications before approving GLP-1 receptor agonists. Step therapy requirements must be met or formally overridden through a state law or plan exception process.

Not medically necessary. The insurer's utilization reviewer applied internal clinical criteria — often MCG or proprietary guidelines — and found your clinical documentation insufficient to establish medical necessity. This determination typically means missing documentation, not that coverage is impossible.

Off-label use characterization. Mounjaro (tirzepatide) prescribed for weight management rather than type 2 diabetes may be denied as off-label use, particularly before Zepbound's market availability. The strength of the clinical evidence (SURMOUNT trials) supports medical necessity arguments for off-label use.

Experimental or investigational classification. Some insurers apply experimental classifications to newer formulations despite FDA approval. For Wegovy (2021 approval) and Zepbound (2023 approval), an experimental classification is factually incorrect and directly challengeable.

How to Appeal a Wegovy or Mounjaro Denial

Step 1: Identify the Denial Basis and Request the Clinical Policy Bulletin

Under ERISA (29 CFR 2560.503-1) and ACA (45 CFR 147.136), you are entitled to the specific clinical policy bulletin used to evaluate your claim. Request this document and compare the insurer's criteria to the FDA-approved indication and to American Obesity Association and Obesity Medicine Association clinical guidelines. Where the insurer's criteria are more restrictive than the FDA indication, document that discrepancy in your appeal.

Step 2: Reframe as Cardiovascular Outcomes Treatment for High-Risk Patients

The SELECT trial (Lincoff et al., NEJM 2023; n=17,604) demonstrated semaglutide 2.4 mg reduced major adverse cardiovascular events by 20 percent (HR 0.80, 95% CI 0.72 to 0.90) in patients with obesity and established cardiovascular disease — independent of weight loss. For patients with prior MI, stroke, or peripheral arterial disease, semaglutide is a cardiovascular outcomes drug, not merely a weight loss medication. This reframing bypasses anti-obesity medication exclusions and shifts the coverage question to cardiovascular treatment, where coverage is rarely excluded.

Step 3: Document All Comorbidities With Objective Clinical Evidence

Your appeal must include a comprehensive comorbidity profile with objective data: HbA1c levels and diabetes management history, blood pressure readings and antihypertensive medication use, lipid panels documenting dyslipidemia, sleep study results for obstructive sleep apnea, cardiovascular risk score (ASCVD 10-year risk calculator), and echocardiography or cardiac imaging if available. Each comorbidity with supporting data strengthens the medical necessity argument independently.

Step 4: Invoke State Step Therapy Override Laws

More than 30 states have enacted step therapy override legislation requiring insurers to waive step therapy requirements when: the required step medication was previously tried and failed, the required medication is contraindicated or causes an adverse reaction, or your physician certifies that delay would cause adverse health outcomes. Document every prior weight management intervention — dates, program, medications tried, dosing, duration, outcomes, and clinical reason for failure or discontinuation. For ERISA self-funded plans, state step therapy override laws do not apply — but many plans have an internal step therapy appeal process or medical exception process.

Step 5: Request a Formulary Exception or Medical Exception

If the plan excludes or non-formulary places Wegovy or Mounjaro, file a formulary exception request. Your prescribing physician must document medical necessity for the specific agent — citing the FDA approval, the clinical trial evidence, the specific comorbidities, and why formulary alternatives are clinically inadequate for your situation. For ACA marketplace plans, formulary exception requests must be decided within 72 hours (standard) or 24 hours (expedited) under 45 CFR 147.136(b).

Step 6: Request External Independent Review: Complete Guide" class="auto-link">External Review and File State Regulatory Complaints

Under ACA (45 CFR 147.136(d)), free independent external review is available after an internal appeal denial. External reviewers applying objective clinical standards have access to the same published evidence — SELECT, SURMOUNT, AHA/ACC guidelines — your physician cites. File simultaneously with your state Department of Insurance for state-regulated plans. For ERISA plans, file a complaint with the Department of Labor EBSA and consider employer HR advocacy — employers ultimately control formulary decisions for self-funded ERISA plans.

What to Include in Your Wegovy or Mounjaro Appeal

• FDA approval documentation for the specific drug and indication (Wegovy for weight management; Zepbound for obesity)
• SELECT trial citation (Lincoff et al., NEJM 2023) if cardiovascular disease is present
• SURMOUNT-1 trial citation (tirzepatide 22.5% weight reduction) for Mounjaro/Zepbound appeals
• Comprehensive comorbidity documentation with objective clinical data and ICD-10 codes
• Step therapy documentation: all prior interventions with dates, outcomes, and failure reasons
• State step therapy override law citation if applicable to your plan type

Fight Back With ClaimBack

Wegovy and Mounjaro denials are reversible when the appeal reframes GLP-1 drugs as cardiovascular and metabolic disease treatments rather than weight loss medications, and documents comorbidities comprehensively. ClaimBack generates a professional appeal letter in 3 minutes, citing SELECT, SURMOUNT, AHA/ACC guidelines, and the ERISA and ACA regulatory framework applicable to your plan. Start your free claim analysis → Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal